David Morton Fox Acquires 3,537 Shares of MediWound (NASDAQ:MDWD) Stock

MediWound Ltd. (NASDAQ:MDWD) Director David Morton Fox purchased 3,537 shares of the company’s stock in a transaction that occurred on Monday, June 1st. The stock was bought at an average price of $14.11 per share, with a total value of $49,907.07. Following the purchase, the director owned 22,283 shares of the company’s stock, valued at approximately $314,413.13. The trade was a 18.87% increase in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

MediWound Trading Down 0.1%

Shares of NASDAQ:MDWD opened at $13.74 on Thursday. The company has a fifty day simple moving average of $16.43 and a 200 day simple moving average of $17.34. The firm has a market cap of $176.58 million, a PE ratio of -6.08 and a beta of 0.16. MediWound Ltd. has a 12-month low of $13.54 and a 12-month high of $22.09.

MediWound (NASDAQ:MDWD) last released its quarterly earnings data on Wednesday, May 27th. The biopharmaceutical company reported ($0.23) EPS for the quarter, topping analysts’ consensus estimates of ($0.65) by $0.42. The firm had revenue of $1.48 million during the quarter, compared to the consensus estimate of $3.37 million. MediWound had a negative net margin of 180.30% and a negative return on equity of 67.22%. During the same quarter in the previous year, the company posted ($0.07) earnings per share. As a group, equities research analysts forecast that MediWound Ltd. will post -2.49 EPS for the current fiscal year.

Wall Street Analyst Weigh In

MDWD has been the subject of a number of research reports. Oppenheimer reaffirmed an “outperform” rating and issued a $32.00 price objective (down from $33.00) on shares of MediWound in a report on Wednesday, May 27th. HC Wainwright reissued a “buy” rating and set a $36.00 price target on shares of MediWound in a report on Thursday, May 28th. Weiss Ratings reissued a “sell (d-)” rating on shares of MediWound in a report on Tuesday, April 21st. Finally, Wall Street Zen raised shares of MediWound from a “strong sell” rating to a “sell” rating in a report on Saturday, May 30th. Two research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $34.00.

Institutional Investors Weigh In On MediWound

Institutional investors have recently bought and sold shares of the stock. Quarry LP acquired a new stake in MediWound in the fourth quarter worth about $26,000. BNP Paribas Financial Markets lifted its holdings in MediWound by 90.4% in the third quarter. BNP Paribas Financial Markets now owns 1,523 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 723 shares during the period. Russell Investments Group Ltd. lifted its holdings in MediWound by 69.1% in the second quarter. Russell Investments Group Ltd. now owns 1,588 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 649 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in MediWound by 22.4% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 5,452 shares of the biopharmaceutical company’s stock worth $85,000 after purchasing an additional 999 shares during the period. Finally, MetLife Investment Management LLC acquired a new stake in MediWound in the fourth quarter worth about $109,000. Institutional investors and hedge funds own 46.83% of the company’s stock.

MediWound Company Profile

MediWound Ltd. (NASDAQ: MDWD) is a biopharmaceutical company headquartered in Yavne, Israel, specializing in the development and commercialization of innovative enzymatic therapies for burn and wound management. Since its establishment, the company has focused on advancing proteolytic enzyme technology to address critical needs in debridement and tissue repair. MediWound operates research and development facilities in Israel and maintains commercial offices in the United States to support its global market presence.

The company’s lead product, NexoBrid®, is an enzyme-based debriding agent designed to selectively remove burn eschar without harming viable tissue.